GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

However, in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or ...

The latest increase reflects the revival of the once-withdrawn antibody-drug conjugate Blenrep, as well as “multiple launch opportunities in the ’26-to-’31 period,” GSK CEO Emma Walmsley ...

Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

Blenrep and depemokimab are expected to launch in 2025, with Blenrep's FDA PDUFA date set for July. Chief Financial Officer Julie Brown noted, "Core operating margin improved to 29.2%, up 130 ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.Most Read from BloombergState Farm Seeks Emergency Californ ...

This year, GSK expects five product approvals, including the relaunch of blood cancer drug Blenrep, which it estimates could eventually reach annual sales of more than 3 billion pounds.

The company cited advances in its research and development pipeline, including plans for additional uses of its cancer drug Blenrep.

For 2025, GSK expects further growth in sales and core earnings, supported by plans to launch five medicines, including a comeback of previously withdrawn multiple myeloma treatment Blenrep.

The increase reflects the inclusion of Blenrep, the significant phase 3 progress since last year and multiple launch opportunities in the 2025 to 2031 period. Price Action: At last check on ...